Survival outcomes of segmentectomy versus lobectomy for T1c non-small cell lung cancer: A systematic review and meta-analysis
- VernacularTitle:肺段切除术与肺叶切除术治疗T1c期非小细胞肺癌的系统评价与Meta分析
- Author:
Xinyu XUE
1
;
Kai ZHAO
1
;
Ningsu CHEN
1
;
Youping LI
1
;
Jiajie YU
2
Author Information
1. 1. Research Center of Clinical Epidemiology and Evidence-Based Medicine, Chinese Evidence-Based Medicine Center, West China Hospital of Sichuan University, Chengdu, 610041, P. R. China
2. 1. Research Center of Clinical Epidemiology and Evidence-Based Medicine, Chinese Evidence-Based Medicine Center, West China Hospital of Sichuan University, Chengdu, 610041, P. R. China 2. Department of Clinical Nutrition, West China Hospital of Sichuan University, Chengdu, 610041, P. R. China
- Publication Type:Journal Article
- Keywords:
Lobectomy;
segmentectomy;
stage T1c;
non-small cell lung cancer;
systematic review/meta-analysis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(03):393-400
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the survival outcomes of segmentectomy versus lobectomy for T1c non-small cell lung cancer (NSCLC). Methods We searched PubMed, EMbase, Cochrane Central Register of Controlled Trials (CENTRAL), CNKI (China National Knowledge Infrastructure), and Wanfang Data, with the search time limit set from the inception of the databases to February 2024. Three researchers independently screened the literature, extracted relevant information, and evaluated the risk of bias of the included literature according to the Newcastle-Ottawa Scale (NOS). Meta-analysis was conducted using STATA 15.1. Results A total of 8 retrospective cohort studies were included, involving 7 433 patients. The NOS scores of the included studies were all ≥7 points. Patients who underwent lobectomy had significantly higher five-year overall survival (OS) rates compared to those who underwent segmentectomy (adjusted HR=1.11, 95%CI 0.99-1.24, P=0.042). Compared with lobectomy, segmentectomy showed no significant difference in adjusted three-year OS rate (adjusted HR=0.88, 95%CI 0.62-1.24) and adjusted five-year lung cancer-specific survival (adjusted HR=1.10, 95%CI 0.80-1.51, P=0.556) of patients with T1c NSCLC. Moreover, there were no differences in the five-year adjusted relapse-free survival (adjusted HR=1.23, 95%CI 0.82-1.85, P=0.319), and adverse events (OR=0.57, 95%CI 0.37-0.90, P=0.015) in the segmentectomy group were significantly less than those in the lobectomy group. Subgroup analysis based on whether patients received neoadjuvant therapy showed that among studies that excluded patients who received neoadjuvant therapy, no significant difference in 5-year adjusted OS rate was observed between the segmentectomy group and lobectomy group (adjusted HR=1.02, 95%CI 0.81-1.28, P=0.870). Conclusion Segmentectomy and lobectomy show no significant difference in long-term survival in stage T1c NSCLC patients, with segmentectomy associated with fewer postoperative complications. Further high-quality research is needed to confirm the comparative efficacy and safety of lobectomy and segmentectomy for T1c NSCLC patients.
